Skip to main content
. 2019 Jun 3;21(7):901–910. doi: 10.1093/neuonc/noz061

Fig. 6.

Fig. 6

The meningioma recurrence score identifies 2 risk groups (high risk vs low risk) that may help individualize adjuvant management decisions such as the need for radiation therapy in patients with meningiomas. Patient tumor samples can be interrogated for DNA methylation profile of selected 9529 probes, and a 5-year methylome-based RFS predictor score is generated. This score is combined with tumor WHO grade and Simpson grade in the meningioma recurrence score to develop an individualized probability of 5-year RFS.